Comparative Pharmacology
Head-to-head clinical analysis: DERMA SMOOTHE FS versus STOBOCLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DERMA SMOOTHE FS versus STOBOCLO.
DERMA-SMOOTHE/FS vs STOBOCLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide is a corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit pro-inflammatory cytokines and reduce inflammation, vasodilation, and edema.
STOBOCLO (bupivacaine and meloxicam) is a dual-acting local anesthetic and NSAID combination. Bupivacaine blocks sodium channels in nerve fibers, preventing nerve impulse conduction and producing local anesthesia. Meloxicam inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing anti-inflammatory and analgesic effects.
Apply topically as a thin film to affected areas twice daily. Maximum weekly dose should not exceed 60 g.
Adults: 5 mg orally once daily, with or without food. Maximum dose: 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours (systemic absorption after topical application); clinical context: prolonged with hepatic impairment.
Terminal elimination half-life is 12-18 hours in adults with normal renal function, requiring dose adjustment in renal impairment.
Primarily renal (90%) as inactive metabolites; <5% unchanged. Biliary/fecal excretion accounts for <10%.
Renal excretion of unchanged drug accounts for 60-70% of elimination; fecal/biliary excretion accounts for 20-30%; the remainder is metabolized hepatically.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid